Ultra-low dose THC
~5 milligrams of THC can go a long way...
Timeline of Research
​
2023: In a rat model of PTSD, an ultra-low dose of THC reduced the fear response via the hippocampus (memory center)
Effects of delta-9 tetrahydrocannabinol on fear memory labilization and reconsolidation: A putative role of GluN2B-NMDA receptor within the dorsal hippocampus
https://pubmed.ncbi.nlm.nih.gov/36549374/
​
2023: In mice, more THC got into their system when administered in a THC- rich extract. Also oral CBD helped with their mechanical pain hypersensitivity
Pharmacokinetics of Orally Applied Cannabinoids and Medical Marijuana Extracts in Mouse Nervous Tissue and Plasma: Relevance for Pain Treatment
https://pubmed.ncbi.nlm.nih.gov/36986714/
​
2022: In songbirds with brain damage, we already knew that CBD helped them to recovery their singing ability & then this research demonstrates that a low dose of THC helps the CBD to work better
Δ9-Tetrahydrocannabinol Differentially Alters Cannabidiol Efficacy in Recovery of Phonology and Syntax Following Damage to a Songbird Cortical-Like Brain Region
https://pubmed.ncbi.nlm.nih.gov/36125410
2022: In a mouse model of fibromyalgia, low-THC cannabis oil reduced sensitivity to pressure & heat as well as reducing depressive behaviors
Broad-spectrum cannabis oil ameliorates reserpine-induced fibromyalgia model in mice
https://pubmed.ncbi.nlm.nih.gov/35988425
​
2022: In humans with PTSD, 7.5 mg THC helped with emotional processing during an emotional regulation task
Cannabinoid modulation of brain activation during volitional regulation of negative affect in trauma-exposed adults
https://pubmed.ncbi.nlm.nih.gov/35981598
​
2022: In a mouse model of Alzheimer’s, an ultra-low dose of THC lessened cognitive impairments
An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer's Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model
https://pubmed.ncbi.nlm.nih.gov/36012711
​
2022: In an older mouse model of Alzheimer’s, low doses of intranasal THC for 3 months significantly slowed memory decline
The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC
https://pubmed.ncbi.nlm.nih.gov/35457070
​
2022: In a patient with mild Alzheimer’s, microdosing of cannabis improved memory
Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: a case report
https://pubmed.ncbi.nlm.nih.gov/35820856
​
2022: In a mouse model of fibromyalgia, cannabis oil with low THC levels helped with pain & touch sensitivities as well as lessening depressive behaviors
Broad-spectrum cannabis oil ameliorates reserpine-induced fibromyalgia model in mice
https://pubmed.ncbi.nlm.nih.gov/35988425
​
2022: In dementia patients, a cannabis oil with 30% CBD & 1% THC helped with agitation & aggression
Effects of Broad Spectrum Cannabidiol Oil on Behavioral Disturbances in Patients with Dementia: A Randomized Clinical Trial
https://assets.researchsquare.com/files/rs-1521853/v1/269f459b-f15e-4535-84b5-c7b5878bc351.pdf?c=1649435492
​
2022: In a mouse model of Alzheimer’s disease, low doses of THC decreased biomarkers of the disease
Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice
https://www.mdpi.com/1422-0067/23/5/2757/htm
​
2022: In children with autism, the use of low doses of CBD & trace amounts of THC decreased behavioral problems, improved cognition & increased social interactions
CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature
https://pubmed.ncbi.nlm.nih.gov/34911567/
​
2021: In humans with Tourette’s, initial promise was seen with a combination of 10 mg of THC + 800 mg of PEA
A Phase-2 Pilot Study of a Therapeutic Combination of Δ 9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome
https://pubmed.ncbi.nlm.nih.gov/34340527/
​
2021: In humans, a look at the pharmacology of taking Spectrum Red softgels (2.5 mg THC, ~.25 mg CBD)
Safety, Pharmacokinetics, and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants
https://pubmed.ncbi.nlm.nih.gov/33848338/
​
2021: In humans with pain, a small amount of THC (2.5 to 10 mg) helps an opioid painkiller to work better
Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model
https://pubmed.ncbi.nlm.nih.gov/33879842/
​
2021: A remarkable case series showing the power of small amounts of synthetic THC (dronabinol) for neuropathic itch
Neuropathic itch treated with oral cannabinoids: A case series
https://pubmed.ncbi.nlm.nih.gov/34692966/
​
2021: In this case study, vaping a small amount of THC helped a patient with her headaches resulting from brain surgery
Significant reduction of symptomatic headache by medical marijuana – Case report
​
2021: In a rat model of seizures, both THC & CBD have antiseizure properties but the most effective is a small amount of THC added to a larger dose of CBD
Antiseizure effects of the cannabinoids in the amygdala-kindling model
https://pubmed.ncbi.nlm.nih.gov/34251027/
​
2020: In humans with MS, an average dose of 4 mg of THC relieved pain, spasticity & sleep disturbances
Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/33387864/
​
2020: In humans with fibromyalgia, low doses of THC helped with symptoms such as pain & fatigue
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
https://pubmed.ncbi.nlm.nih.gov/33118602/
​
2019: A review of the brain benefits of ultra-low dose THC
Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC
https://pubmed.ncbi.nlm.nih.gov/30864864/
​
2018: In humans with sleep apnea, 2.5 to 10 mg of THC helped improve scores
Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea
https://pubmed.ncbi.nlm.nih.gov/29121334/
​
2018: In older mice, low doses of THC made them perform better on a number of behavioral tests
Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol
https://pubmed.ncbi.nlm.nih.gov/29107185/
​
2017: In older mice, a chronic low dose of THC restores cognitive function
A chronic low dose of Δ 9-tetrahydrocannabinol (THC) restores cognitive function in old mice
https://pubmed.ncbi.nlm.nih.gov/28481360/
​
2015: In older humans with dementia, low doses of THC safe & well tolerated
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
https://pubmed.ncbi.nlm.nih.gov/25752889/
​
2015: In humans with Alzheimer’s, low doses of THC found safe & well tolerated
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial
https://pubmed.ncbi.nlm.nih.gov/25972490/
​
2014: In a mouse model of neuroinflammation, very low doses of THC protected the brain
Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage
https://pubmed.ncbi.nlm.nih.gov/25042014/
​
2013: In mice, low dose of THC protected the heart from insults
An ultra-low dose of tetrahydrocannabinol provides cardioprotection
https://pubmed.ncbi.nlm.nih.gov/23537701/
​
2012: In humans with cancer, low (1-4 sprays) & medium doses of Sativex were more effective than placebo for pain
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
https://pubmed.ncbi.nlm.nih.gov/22483680/
​
2012: In mice, the mechanisms of how THC protects the brain from neuronal insults
Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling
https://pubmed.ncbi.nlm.nih.gov/22821081/
​
2011: In mice exposed to the neurotoxic drug pentylenetetrazole, a low dose of THC before or after the exposure protected the brain
Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage
https://pubmed.ncbi.nlm.nih.gov/21315768/
2011: In humans with dementia, 2.5 mg of THC helped with agitation
Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia
https://pubmed.ncbi.nlm.nih.gov/21364345/
​
2010: In mice, a very low dose of THC altered the memory for 5 months
Long-term consequences of a single treatment of mice with an ultra-low dose of Delta9-tetrahydrocannabinol (THC)
https://pubmed.ncbi.nlm.nih.gov/19766676/
​
2008: In mice, a low dose of THC lowered performance in a maze test
Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice
https://pubmed.ncbi.nlm.nih.gov/17888506/
​
2007: In young adults, 5 mg of THC altered their reactions to risky decision making in gambling scenarios
The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults
https://pubmed.ncbi.nlm.nih.gov/17006433/
​
2007: In mice, a low dose of THC altered performance in a water maze
A single low dose of tetrahydrocannabinol induces long-term cognitive deficits
https://pubmed.ncbi.nlm.nih.gov/17092651/
​
2006: In humans with severe nighttime agitation, 2.5 mg of THC helps reduce nocturnal motor activity & agitation
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
https://pubmed.ncbi.nlm.nih.gov/16521031/
​
2006: In humans, low doses of THC had differential gender effects on spatial memory
Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults
https://pubmed.ncbi.nlm.nih.gov/16177808/
​
2005: In mice, low dose of THC protected from atherosclerosis
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
https://pubmed.ncbi.nlm.nih.gov/15815632/
​
2004: In humans with MS, THC reduced pain at 5 to 10 mg
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
https://pubmed.ncbi.nlm.nih.gov/15258006/
​